Impatto economico della gestione degli eventi correlati all’apparato scheletrico (SREs) in pazienti con metastasi ossee da tumori solidi nelle regioni italiane

Journal title MECOSAN
Author/s Maria Caterina Cavallo, Simone Gerzeli, Carla Rognoni, Alessandra Cheli, Claudio Pelosi, Santini Santini
Publishing Year 2015 Issue 2014/91 Language Italian
Pages 17 P. 43-59 File size 541 KB
DOI 10.3280/MESA2014-091003
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

Article preview

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

Bone metastases are frequently associated to the management of Skeletal Related Events (SRE) such as pathological fractures, spinal compression, radiation to bone, surgery to bone. These events increase patient’s morbidity and the need for associated healthcare resources. Starting from STARS study - that measured the utilization of healthcare services in four European countries including Italy - the regional annual budget impact of managing SREs related to cancers of the breast, prostate and solid tumors in different Italian regions has been estimated. The regional budget impact was estimated based on the reimbursement tariffs related to the mix of services involved in the management of the SREs as reported by the STARS study. The average impact for the management of SREs amounts to about EUR 3.664. Estimating 56.697 annual SREs in Italy, the overall impact on the regional health systems is approximately 208 million Euros. Any intervention that can reduce the frequency of SREs is desirable to increase patients’ quality of life and to decrease the overall economic burden.

Keywords: Skeletal related events, cost evaluation.

  1. AIOM (2013). Linee guida trattamento delle metastasi ossee. Testo disponibile al sito http://www.aiom.it/C_Common/Download.asp?file=/$Site$/Attivita_Scientifica/Linee_Guida/2013/LG_Metastasi_Ossee_v8_10.10.13.pdf.
  2. AIS (2012). Testo disponibile al sito http://www.ais-sanita.it/ricerca-sviluppo-e-tecnologia/1518-metastasi-ossee-studio-51-pazienti-ignari-di-esserne-vittime.html.
  3. Amadori D., Ibrahim T., Fabbri M. (2003a). Storia naturale ed epidemiologia. In: Amadori D., Cascinu S., Conte P.F. (eds). Osteoncologia, un approccio multidisciplinare. Milano: Excerpta Medica, pp. 29-41.
  4. Amadori D., Ibrahim T., Fabbri M. (2003b). Clinica e complicanze delle metastasi ossee. In: Amadori D., Cascinu S., Conte P.F. (eds). Osteoncologia, un approccio multidisciplinare. Milano: Excerpta Medica, pp. 59-69.
  5. Berardi R., Pierantoni C., Scartozzi M., Cascinu S. (2010). Natural history and epidemiology. In: Amadori D., Cascinu S., Conte PF., Ibrahim T. (eds). Osteo-Oncology Textbook. Milano: Poletto
  6. Editore.
  7. Coleman R.E. (2004). Bisphosphonates: clinical experience. Oncologist, 9, Suppl 4: 14-27.
  8. 10.1634/theoncologist.9-90004-14.
  9. Coleman R.E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res., 12: 6243-6249.
  10. Delea T., Mckiernan J., Brandman J. et al. (2006). Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol, 4 (7): 341-347.
  11. EMA (2011). European Medicines Agency. Assessment Report for Xgeva (EPAR). International non-proprietary name: denosumab. Testo disponibile al sito http://www.ema.europa.eu/ema/index . jsp?curl=pages/medicines/human/medicin e s / 0 0 2 1 7 3 / huma n _ m e d _ 0 0 1 4 6 3 .
  12. jsp&mid=WC0b01ac058001d124.
  13. Garzon-Rodriguez C., Hoefeler H., Duran I. et al. (2011). Skeletal-related event (SRE) health resource utilisation (HRU) in patients with bone metastases: results from a prospective multinational observational study. Poster presented at the 2011 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology International Symposium. Athens, Greece, June 23-25.
  14. Hage W.D., Aboulafia A.J., Aboulafia D.M. (2000). Incidence, location and diagnostic evaluation of metastatic bone disease. Orthop Clin North Am, 31: 515-528. DOI: 10.1016/s0030-5898(05)70171-1
  15. Hechmati G., Cure S., Gouepo A. et al. (2013). Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ, 16 (5): 691-700. DOI: 10.3111/13696998.2013.779921
  16. IARC, Globocan (2008). Testo disponibile al sito http://globocan.iarc.fr/Default.aspx.
  17. Ibrahim T., Mercatali L., Casade R., Sabbatini R. (2010). Clinical manifestation. In: Amadori D., Cascinu S., Conte P.F., Ibrahim T. (eds). Osteo-Oncology Textbook. Milano: Poletto Editore.
  18. Ibrahim T., Tonini G., Amadori D., Santini D. (2013). Metastasi ossee. In: Labianca R., Cascinu S. La Medicina Oncologica – Diagnosi, Terapia e gestione clinica. Milano: Elsevier Masson Italia.
  19. Lage M.L., Harrison D.J., Barber B.L., Jun S. (2007). Burden of hospitalizations associated with skeletal-related events in patients with breast cancer or lung cancer and bone metastases or multiple myeloma. Poster presented at the ISPOR 12th Annual International Meeting, Arlington, Virginia, May 19-23.
  20. Lecci F., Longo F., Ricci A. (2012). Modelli assistenziali costi dei malati di SLA: evidenze del caso lombardo. Mecosan, 83: 45-62.
  21. Ministero della Salute (2007). Progetto Mattoni, Mattone 11 – Pronto soccorso e sistema 118. Testo disponibile al sito http://www.mattoni.salute.gov.it/mattoni/documenti/11_Valutazione_costi_dell_emergenza.pdf.
  22. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., Mcfadden E.T., Carbone P.P. (1982). Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol, 5: 649-655. DOI: 10.1097/00000421-198212000-00014
  23. Roth E.S., Fetzer D.T., Barron J. (2009). Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer, 9: 274. DOI: 10.1186/1471-2407-9-274
  24. Rubens R.D. (1998). Bone metastases the clinical problem. Eur J Cancer, 34 (2): 210-213. DOI: 10.1016/s0959-8049(97)10128-9
  25. Santini D., Vincenzi B., Pantano F. et al. (2011). Targeting bone metastases starting from the preneoplastic niche: home sweet home. Breast Cancer Res, 13 (4): 111. DOI: 10.1186/bcr2911.SantiniD.,TampelliniM.,VincenziB.etal.(2012).Naturalhistoryofbonemetastasisincolorectalcancer:finalresultsofalargeItalianbonemetastasesstudy.AnnOncol,23(8):2072-2077.DOI:10.1093/annonc/mdr572
  26. Santini D., Intagliata S., Ibrahim T. et al. (2013). Natural history of malignant bone disease in nonsmall cell lung cancer: Preliminary results of a multicenter bone metastasis survey. J Clin Oncol, 31, suppl., abstre19084.

Maria Caterina Cavallo, Simone Gerzeli, Carla Rognoni, Alessandra Cheli, Claudio Pelosi, Santini Santini, Impatto economico della gestione degli eventi correlati all’apparato scheletrico (SREs) in pazienti con metastasi ossee da tumori solidi nelle regioni italiane in "MECOSAN" 91/2014, pp 43-59, DOI: 10.3280/MESA2014-091003